LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: A comparative analysis of tranexamic acid dosing strategies in traumatic major hemorrhage.

Gunn, Finn / Stevenson, Rheanna / Almuwallad, Ateeq / Rossetto, Andrea / Vulliamy, Paul / Brohi, Karim / Davenport, Ross

The journal of trauma and acute care surgery

2023  Volume 96, Issue 2, Page(s) 216–224

Abstract: Introduction: Tranexamic acid (TXA) is a life-saving treatment for traumatic hemorrhage, but the optimal dosing regimen remains unknown. Different doses and treatment strategies have been proposed, including single bolus, repeated bolus, or bolus plus ... ...

Abstract Introduction: Tranexamic acid (TXA) is a life-saving treatment for traumatic hemorrhage, but the optimal dosing regimen remains unknown. Different doses and treatment strategies have been proposed, including single bolus, repeated bolus, or bolus plus infusion. The aim of this study was to determine the effect of different TXA dosing strategies on clinical outcomes in bleeding trauma patients.
Methods: Secondary analysis of a perpetual cohort study from a UK Level I trauma center. Adult patients who activated the local major hemorrhage protocol and received TXA were included. The primary outcome was 28-day mortality. Secondary outcomes were 24-hour mortality, multiple organ dysfunction syndrome, venous thromboembolism, and rotational thromboelastometry fibrinolysis.
Results: Over an 11-year period, 525 patients were included. Three dosing groups were identified: 1 g bolus only (n = 317), 1 g bolus +1 g infusion over 8 hours (n = 80), and 2 g bolus (n = 128). Demographics and admission physiology were similar, but there were differences in injury severity (median Injury Severity Score, 25, 29, and 25); and admission systolic blood pressure (median Systolic Blood Pressure, 99, 108, 99 mm Hg) across the 1-g, 1 g + 1 g, and 2-g groups. 28-day mortality was 21% in each treatment group. The incidence of multiple organ dysfunction syndrome was significantly higher in the bolus plus infusion group (84%) vs. 1 g bolus (64%) and 2 g bolus (62%) group, p = 0.002, but on multivariable analysis was nonsignificant. Venous thromboembolism rates were similar in the 1-g bolus (4%), 2 g bolus (8%) and bolus plus infusion groups (7%). There was no difference in rotational thromboelastometry maximum lysis at 24 hours: 5% in both the 1-g and 2-g bolus groups vs. 4% in bolus plus infusion group.
Conclusion: Clinical outcomes and 24-hour fibrinolysis state were equivalent across three different dosing strategies of TXA. Single bolus administration is likely preferable to a bolus plus infusion regimen.
Level of evidence: Therapeutic/Care Management; Level III.
MeSH term(s) Adult ; Humans ; Tranexamic Acid/therapeutic use ; Antifibrinolytic Agents/therapeutic use ; Venous Thromboembolism/chemically induced ; Cohort Studies ; Multiple Organ Failure ; Hemorrhage/drug therapy ; Hemorrhage/etiology
Chemical Substances Tranexamic Acid (6T84R30KC1) ; Antifibrinolytic Agents
Language English
Publishing date 2023-10-24
Publishing country United States
Document type Journal Article
ZDB-ID 2651070-4
ISSN 2163-0763 ; 2163-0755
ISSN (online) 2163-0763
ISSN 2163-0755
DOI 10.1097/TA.0000000000004177
Shelf mark
Zs.A 127: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top